CloseCategory: Diabetes Research News
-
The Fascinating History of Diabetes
Introduction to Mellitus What’s Mellitus? Unraveling the threads of human history often reveals fascinating insights into our shared past. One such thread that has intricately woven itself into our narrative […]
-
FDA Approves Lantidra – a promising cellular therapy for Type 1 Diabetes
Big Picture · On June 28, the FDA approved Lantidra, which is the first cellular therapy to treat type one diabetes. (FDA Press release) · 21 out of 30 participants […]
-
DRC’s investment in T1D cures continues! RFA 2023 is now open!
Diabetes Research Connection’s next round of type 1 diabetes (T1D) research funding has begun. We are excited to announce that our 2023 Request for Application (RFA) period is NOW OPEN! We […]
-
Potential Benefits of Incorporating C4H11N5 in Type 1 Diabetes Treatment
Metformin: A Potential Game-Changer in Type 1 Diabetes Management The journey of managing diabetes is a complex one, impacted by a myriad of factors affecting blood sugar levels. One such […]
-
Congratulations to our newest research grant awardees!
Join us in cheering on these new T1D researchers! Every year, hundreds of new T1D researchers for our prestigious research grant. This year, we were thrilled to review an impressive […]
-
Research Findings May Provide Answers to Diabetes Complication of Peripheral Neuropathy
Approximately half of the people with type 1 or type 2 diabetes experience peripheral neuropathy—weakness, numbness, and pain, primarily in the hands and feet. New discoveries by a team of […]
-
DRC’s Take on, “The type 1 diabetes gene TYK2 regulates βcell development and its responses to interferon-α”
Understanding TYK2: The Diabetes Gene Role of TYK2 in Human Genome In the intricate world of our genome, the TYK2 Diabetes Gene (Tyrosine Kinase 2) gene holds a special place. […]
-
DRC Is Excited to Share This Breaking T1D News Announced Yesterday by the FDA
The FDA has just approved Provention Bio’s Tzield™ (teplizumab-mzwv) – the first drug therapy that can delay the onset of type-1 diabetes (T1D) for those at risk of developing the […]
-
November 2022 Newsletter
Let’s be honest. With the hectic pace of life, you might wonder why you should spend your precious time reading a newsletter, especially one about diabetes research. But have you […]
-
For the Good of Neural Tissues and Pancreatic Islets
While organs can be transplanted from deceased donors, tissues from the nervous system rapidly lose viability. The mechanisms of neuronal death, and the potential for reversing it, remain poorly defined. […]
-
DRC’s Take: Vertex to Acquire Chief T1D Stem Cell Competitor in All-Cash Deal
Vertex, whose VX-880 stem cell therapy for type 1 diabetes has cleared clinical proof of concept, is acquiring ViaCyte, a private biotech that has also reached clinical trials with its […]
-
DRC in the Community: President and Chair, C.C. King’s Presentation on Insights into Medical Research
On Monday, May 23rd, DRC’s President and Chair, C.C. King, Ph.D., spoke at Del Mar Foundation’s speaker series, DMFTalks. Over 30 members of the community came to listen to C.C. […]
